![Ivan Bergstein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ivan Bergstein
Director Ejecutivo en STEMLINE THERAPEUTICS, INC. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Kenneth Hoberman | M | 59 |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 11 años |
David Gionco | M | 63 | 10 años | |
Mark Sard | M | 59 |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 años |
Daniel Hume | M | 57 |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 5 años |
Jeffrey Levitt | M | - | 6 años | |
Matt Hoberman | M | - |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | 2 años |
Nassir Habboubi | M | - | 3 años | |
Peter McDonald | M | - |
Lirum Therapeutics, Inc.
![]() Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Shay Shemesh | M | 41 | 5 años | |
J. Buchi | M | 69 | 4 años | |
Eric Dobmeier | M | 55 | 6 años | |
Stephen Hall | M | 73 | - | |
Kenneth Zuerblis | M | 64 | 8 años | |
Christopher L. Brooks | M | - | - | |
Robert Francomano | M | 58 | 5 años | |
Jonathan Schwartz | M | 60 | 2 años | |
Enrique Poradosu | M | 58 | 4 años | |
Darren Cline | M | 59 | - | |
Mark Jacobson | M | 40 | 5 años | |
John Cavan | M | 65 | 6 años | |
Ronald Bentsur | M | 58 | 11 años | |
Thomas P. Cirrito | M | 51 | - | |
Alan Forman | M | 58 | 5 años | |
Eric Rowinsky | M | 67 | 5 años | |
Trishna Goswami | M | 46 | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 25 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Ivan Bergstein
- Red Personal